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Abstract
Objective—Signs of a parasympathetic
dysfunction have been revealed in pri-
mary Sjögren’s syndrome (SS). Its role in
the pathogenesis and the clinical picture
of the disease is not clear. To investigate
the responsiveness of SS patients to a
cholinergic agonist, a model was used
involving examination of the cutaneous
microcirculation. The microvascular re-
sponse to the administration of carbachol
was measured, a muscarinic cholinergic
agonist.
Methods—Twenty two SS patients and 12
controls were examined. Carbachol and
0.9% saline solution were administered
intracutaneously into the forearm skin at
two distinct places. Skin blood flow (SBF)
in the injected areas was measured con-
tinuously before and for 10 minutes after
the injections by means of a laser Doppler
perfusion monitor. The increase in SBF in
response to carbachol (dSBF), reflecting
vasodilatation, was calculated by a for-
mula including the baseline and the maxi-
mum SBF values after the injections of
carbachol and saline solution.
Results—The vasodilatation was signifi-
cantly lower in SS patients than in the
controls (mean dSBF: 2.1 (range: 1.0–4.5)
versus 3.3 (range: 1.7–7.6), p=0.02). With
non-responder patients defined as those
in whom a smaller response was observed
than in any of the controls, 11 of the 22 SS
patients proved to be non-responders to
carbachol. Comparisons of demographic,
clinical and laboratory characteristics
and HLA class II genotypes between
responder and non-responder SS patients
did not show any significant diVerences.
Conclusions—A diminished or absent re-
sponse to carbachol indicates a choliner-
gic dysfunction in SS patients. A
disturbance in the neurotransmission at a
receptorial or postreceptorial level is
hypothesised. Unresponsiveness to
cholinergic stimuli may contribute to exo-
crine insuYciency.
(Ann Rheum Dis 2000;59:48–53)
Dry mouth and dry eyes, the two fundamental
symptoms of primary Sjögren’s syndrome
(SS), have previously been regarded solely as
direct consequences of the loss of functioning
glandular tissue caused by an autoimmune
inflammatory process. However, this concep-
tion is now increasingly questioned.1 2 The
symptoms of dryness and the quantitatively
determined saliva and tear production may
vary greatly during the course of the disease,
even without treatment, and their spontaneous
improvement is often observed for varying
periods. A marked discrepancy has been
reported between the degree of exocrine insuf-
ficiency and the histologically verified intensity
of the inflammatory infiltration in the salivary
glands.3 In human and animal experiments,
several types of abnormalities of the autonomic
nervous system have been demonstrated in
SS.4–10
The question of whether an impairment of
parasympathetic innervation may play a part in
the elicitation of exocrine insuYciency in SS
remains an issue to be examined. Despite pre-
vious work, results of human functional studies
on the parasympathetic nervous system in SS
patients are by no means numerous. If a postu-
lated cholinergic dysfunction does exist, it is
not known whether it is caused by a central or
a peripheral nervous system dysfunction, or
whether it reflects a disorder of the parasympa-
thetic innervation at a receptorial or postrecep-
torial level. Nor is it clear whether the
acetylcholine transmitter system or a non-
adrenergic, non-cholinergic transmitter (for
example, vasoactive intestinal polypeptide
(VIP)) system colocalised in the cholinergic
nerve terminals is involved.11
For these reasons, we set out to examine the
response to the administration of a muscarinic
cholinergic agonist, carbachol, in SS patients
and to compare it with that in healthy controls.
To measure this response, we established a
model involving examination of the cutaneous
microcirculation. A cholinergic vasodilatory
mechanism of the human skin blood vessels has
long been verified.12–14 As this is similar in many
respects to the cholinergic innervation of the
salivary glands,13 we decided to use this experi-
mental setting to test the hypothesis that a
cholinergic dysfunction exists in SS patients.
Methods
PATIENTS AND CONTROLS
Twenty two primary SS patients (20 female
and 2 male) were enrolled in the study. All were
diagnosed as having SS by the European Com-
munity criteria15 at the Division of Autoim-
mune Diseases at the 1st Department of Inter-
nal Medicine, Albert Szent-Györgyi Medical
University, Szeged, Hungary. The average age
of the patients was (mean (SD)) 50.6 (13.2)
years (33–60). The average time since the first
symptom had appeared was (mean (SD))11.5
(5.2) years (4–24), while the average time since
the establishment of the diagnosis was (mean
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(SD)) 9.1 (6.7) years (3–20). In 18 of the 22
patients, a minor salivary gland biopsy had
been performed. In 17 of these 18 patients,
histological examination revealed focal lym-
phocytic sialadenitis, meeting the histological
criteria of SS, while in one patient a negative
result was obtained. In this latter patient and in
the four patients on whom no biopsy was per-
formed, the appropriate number of other crite-
ria for the diagnosis of SS was met. All patients
were regularly followed up. To exclude other
factors that might possibly influence the
microcirculatory physiology, SS patients older
than 60 years, those who had hypertension or
clinical evidence of arteriosclerosis (coronary
heart disease, arteriosclerotic cerebral disease
or arteriosclerosis in other organs) or periph-
eral neuropathy, and those who regularly took
â-adrenergic blockers, calcium channel block-
ers, pentoxyphylline, or other drugs with
vasodilatory or anticholinergic properties, were
regarded as not eligible for the study. For the
same reason, the use of non-steroidal anti-
inflammatory drugs was suspended at least five
days before the examinations. The patients
were asked to refrain from smoking or the
drinking of coVee on the day of the examina-
tion.
Twelve healthy, age and sex matched people
were examined as controls. None of these sub-
jects had any known illness, or were taking any
regular medication. All gave their informed
consent to the procedure and the study design
was accepted by the Medical Ethics Board of
Albert Szent-Györgyi Medical University.
EXAMINATION OF THE CUTANEOUS VASCULAR
RESPONSE
During examinations, the patients and controls
were in the supine position. The skin blood
flow (SBF) was measured with a laser-Doppler
flowmeter (Penflux, Perimed) attached to the
skin on the flexor surface of the right forearm,
and blood flow values were expressed in
arbitrary units.16 Three ECG electrodes were
attached to the chest and the heart rate was
monitored continuously, as was the blood
pressure by means of a photoplethysmographic
blood pressure monitor (Finapres 2300, Ohm-
eda) attached to a finger of the right hand (beat
to beat registration). The subjects were asked
to lie at rest with their eyes closed. The room
temperature was kept constant (20°C ± 1°C)
and all disturbing factors were excluded. The
baseline SBF was recorded for five minutes; the
blood flow was stable by the end of this period
and the SBF value measured at five minutes
was defined as SBF basal. Then 0.1 ml of car-
bachol (Miostat, Alcon, USA), a muscarinic
receptor agonist, was injected intracutaneously
into the forearm skin. As control, almost
simultaneously, 0.1 ml of 0.9% saline solution
was injected similarly into the forearm skin at
approximately 10 cm from the other injection
site. SBF was measured simultaneously at the
two injection sites for another 10 minutes and
the highest deviations from the baseline flow
values were designated SBF final.
All recorded data (heart rate, systolic and
diastolic arterial pressure and SBF) were
stored in a computer database and were
analysed by means of a self developed software.
The change in SBF in response to the injection
of carbachol (dSBF) was calculated using the
following formula:
Thus, dSBF is the ratio of the SBF values
measured after and before the injection of car-
bachol divided by the same ratio for the control
solution of physiological saline. This calcula-
tion allowed us to eliminate the absolute flow
values and also to eliminate possible non-
specific microcirculatory eVects of the intracu-
taneous injection. In every subject, the mean
values of the RR intervals on the ECG, and the
systolic, diastolic and mean arterial pressures
were also recorded. The cutaneous vascular
resistance (CVR) was calculated by dividing
the mean arterial pressure by SBF, while dCVR
was calculated with a formula analogous to that
for dSBF.
LABORATORY EXAMINATIONS
Laboratory examinations were performed as
follows: anti-SSA and anti-SSB antibodies:
enzyme linked immunosorbent assay (Ep-
ignost, Leonding/Linz, Austria); antinuclear
antibodies: indirect immunofluorescence assay,
using rat liver as substrate; IgM rheumatoid
factor: quantitative measurements by immuno-
turbidimetry (Boehringer Mannheim, Ger-
many). HLA DRB1, DQA1 and DQB1
genotyping was performed by using methods
described in detail by others.17–20 Schirmer’s
test and sialometry were performed within one
year from the examinations in all SS patients.
As sialometric examination, we assessed the
unstimulated whole saliva production in 10
minutes. Skin dryness was scored on a scale
0–IV on the basis of the patients’ reports of the
severity of dry skin complaints and physical
examination of the skin, as follows: grade 0: no
dry skin; grade I: a transient feeling of skin
dryness not requiring treatment, and no objec-
tive signs of dry skin; grade II: a recurrent feel-
ing of skin dryness requiring treatment with
hydrating lotions, and objective signs of
Table 1 Occurrences of main organ manifestations and
laboratory variables in primary Sjögren’s syndrome
patients (n=22)
Organ manifestations and laboratory variables
Number of
patients (%)
Articular involvement* 17 (77)
Renal involvement† 4 (18)
Bronchitis sicca 4 (18)
Pulmonary fibrosis 2 (9)
Raynaud’s phenomenon 6 (27)
Skin vasculitis 3 (14)
MALT lymphoma in parotid gland 2 (9)
Anaemia‡ 6 (27)
Hypergammaglobulinaemia§ 15 (68)
Antibody positivity
Anti-SSA 14 (64)
Anti-SSB 9 (41)
IgM rheumatoid factor 18 (82)
Antinuclear antibody 18 (82)
*Clinically evident arthritis or persistent arthralgia without
objective physical signs. †Chronic tubulointerstitial nephritis or
renal tubular acidosis. ‡Haemoglobin <100 g/l not attributable
to causes other than SS. §ã globulin >16 g/l.
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decreased sweat production; grade III: a
continuous feeling of skin dryness revealed by
topical treatment, and severely dry skin with
fine scaling; grade IV: a continuous feeling of
skin dryness not revealed by topical treatment,
and very severely dry skin with excoriations
and mild loss of hair.
STATISTICAL ANALYSIS
DiVerences between means were calculated
with an independent sample t test, except for
the comparison of the means of dSBF values,
where Wilcoxon’s t test was applied because of
the non-parametric distribution of the ele-
ments of the samples. For the comparisons of
frequencies, Fisher’s exact test was used, with
Bonferroni’s correction when the examined
variable had more than two possible values (for
example, HLA genotype). To investigate corre-
lations with dSBF, Spearman’s signed rank test
or linear regression analysis was applied.
Statistical calculations were performed with
SPSS software. Values in the text are expressed
as mean (SD). The level of significance was
defined as p<0.05.
Results
Table 1 gives details relating to the occurrences
of the main systemic organ manifestations of
SS and the various laboratory parameters in
the 22 patients.
Table 2 reports the average values of the
most important haemodynamic variables in the
two groups recorded during the examinations
of the cutaneous microcirculation. We present
here the means of the changes in the local
blood flow in response to carbachol
(SBFfinal,carbachol/SBFbasal,carbachol) and
physiological saline solution (SBFfinal,saline/
SBFbasal,saline), the dSBF values (which are
specific indicators of the cutaneous vasodilata-
tion in response to the cholinergic agonist), and
also the corresponding values of the change in
CVR. The means of the continuously recorded
values of the RR intervals on the ECG and of
systemic arterial blood pressure are also
included in table 2.
In the event of a positive vascular reaction,
the blood flow started to increase within 30
seconds after the injection of carbachol and
reached a new steady state approximately 4–7
minutes later, then remaining unchanged until
the end of the examination. In the controls, the
average dSBF was 3.30 (1.79), which was sig-
nificantly higher than the average dSBF in SS
patients (2.07 (1.12)) (p=0.019) (fig 1). In the
controls, the dSBF values reflected a 1.66–7.6-
fold increase in microcirculatory blood flow
after the injection of carbachol. However, in a
relatively high proportion of the SS patients,
the reaction to the administration of carbachol
was small or virtually absent, while in other
patients a marked vasodilatation was observed.
We defined a positive microvascular reaction to
carbachol in the SS patients as a dSBF value
higher than the smallest dSBF value in the
group of healthy controls. Following this
definition, exactly half of the SS patients (11 of
22) could be considered to be non-
responders—that is, producing a less than
1.66-fold increase in the microcirculatory
blood flow—while the other half of the patients
were regarded as responders to carbachol on
Table 2 Comparison of certain haemodynamic variables in primary Sjögren’s syndrome (SS) patients and controls recorded during the blood flow
examinations
Group
SBFfinal,carbachol/
SBFbasal,carbachol
SBFfinal,saline/
SBFbasal,saline dSBF dCVR Mean RR (msec)
Mean SBP
(mm Hg)
Mean MBP
(mm Hg)
Mean DBP
(mm Hg)
SS patients 1.89 (1.05)* 0.94 (0.29) 2.07 (1.12)† 0.64 (0.32)‡ 827.9 (109.6) 132.4 (22.0) 95.9 (16.5) 76.3 (14.9)
Controls 2.72 (1.27) 0.86 (0.19) 3.30 (1.79) 0.38 (0.17) 797.0 (117.3) 128.6 (14.9) 93.8 (9.8) 74.9 (7.5)
Data shown as mean (SD). SBF: skin blood flow; CVR: cutaneous vascular resistance; RR: RR interval on ECG; SBP: systolic arterial blood pressure; MBP: mean
arterial blood pressure; DBP: diastolic arterial blood pressure. SBF and CVR values are in arbitrary units. For the calculation of dSBF and dCVR, see the text (Meth-
ods section). *p=0.048, †p=0.019, ‡p=0.013.
Figure 1 Distribution of dSBF values in primary Sjögren’s syndrome (SS) patients and healthy controls. dSBF: change
in skin blood flow in response to the injection of carbachol. Continuous lines indicate means. Values above the dashed lines
indicate a positive response to carbachol.
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the basis of the pronounced vasodilatation (a
more than 1.66-fold increase in SBF).
We examined whether there was any diVer-
ence in certain demographic characteristics or
in the frequencies of certain clinical organ
involvements between the SS patients defined
as non-responders or as responders to carba-
chol (table 3). The age of the patients and the
time since the appearance of the first symptom
of SS was similar in the two groups. Similarly,
when tested by linear regression analysis, the
above variables did not demonstrate any corre-
lation with dSBF (data not shown). No statisti-
cally significant diVerence was revealed be-
tween the two groups in the occurrence of any
of the main organ manifestations. However, it
is noteworthy that all the examined organ
involvements occurred more frequently in the
responder patients (with the exception of
pulmonary fibrosis, which occurred in one
patient in each of the subgroups) (table 3). Dry
skin is a common complaint in SS patients. In
table 4, we present the proportions of patients
with varying degrees of severity of skin dryness.
We checked whether there was a correlation
between the reactivity of the cutaneous micro-
circulatory vessels to carbachol (dSBF) and the
degree of skin dryness, which is predominantly
a consequence of the insuYciency of the
exocrine glands of the skin; the answer proved
negative. The two subgroups were also compa-
rable as concerns the average values of tear and
saliva production (mean tear flow with Schirm-
er’s test: 4.0 (2.12) v 4.45 (2.21) mm/5
minutes, unstimulated whole saliva flow: 0.34
(0.28) v 0.32 (0.28) ml/10 minutes in the non-
responders and in the responders, respec-
tively).
The frequencies of anti-SSA, anti-SSB, IgM
RF and ANA positivity, and also the average
levels of laboratory markers of a chronic
autoimmune inflammatory process, in particu-
lar the erythrocyte sedimentation rate, fibrino-
gen concentration, anaemia and ã globulin
concentration, did not diVer significantly in the
two subgroups of primary SS patients. No
HLA DR, DQA1 and DQB1 allele occurred
more frequently in one subgroup than in the
other, although, in view of the relatively small
number of patients and the heterogeneity of the
genotypes of the examined persons, a statisti-
cally significant diVerence is hardly to be
expected (data not shown).
The drug treatment applied throughout the
course of the illness was also surveyed. The
proportions of patients treated with non-
steroidal anti-inflammatory drugs, hydroxy-
chloroquine or corticosteroids were similar in
the two subgroups. Two patients were receiving
regular corticosteroid treatment and five hy-
droxychloroquine treatment at the time of the
examination; the use of these drugs did not
seem to influence the microcirculatory re-
sponse to carbachol, as indicated by the similar
proportions of users in the responder and non-
responder subgroups.
Discussion
The purpose of this study was to determine the
proportion of primary SS patients who demon-
strate signs of a cholinergic dysfunction, and to
evaluate whether there is a relation between the
presence of a cholinergic dysfunction and cer-
tain clinical, serological and genetic character-
istics of the disease. The importance of this
question stems from the fact that the salivary
glands are richly innervated by cholinergic
nerve fibres, and, if the hypothesis that there is
a disturbance in the cholinergic innervation
proves true, this may provide new aspects as
regards the pathogenesis of the sicca symptoms
in SS. The issue of abnormalities in the
parasympathetic nervous system in SS has
arisen in previous human or animal studies in
which various stages of the parasympathetic
innervation pathway were investigated. Mandl
et al6 and Andonopoulos et al7 detected
autonomic neuropathy, mainly aVecting the
parasympathetic nerves. Santavirta et al8 dem-
onstrated that the salivary outputs of VIP
(considered a marker of the parasympathetic
innervation) and of neuropeptide Y (a marker
of sympathetic innervation) were both in-
creased as compared with healthy controls.
They suggested that this phenomenon is asso-
ciated with an altered response to stress in SS
patients. In immunohistological examinations,
Konttinen et al4 found that VIP containing
parasympathetic fibres were absent from re-
gions of the parotid glands where inflammatory
cell infiltration and acinar atrophy were severe.
Circulating antibodies against rat parotid M3
muscarinic cholinergic receptors were detected
by Bacman et al.9 Törnvall et al5 reported that
the expression of the âII and á isoforms of pro-
tein kinase C, a crucial member of the intracel-
lular second messenger pathway of cholinergic
neurotransmission, was deficient on the sali-
vary gland acinar epithelial cells in SS patients
as compared with controls. In contrast with
healthy controls, the î and âII isoforms were
undetected on the myoepithelial cells in SS
patients. These findings are suggestive of a
postreceptorial disturbance of the cholinergic
innervation.
In this study, we examined the cutaneous
cholinergic vasodilatation in SS patients in
response to the local administration of a
Table 3 Demographic characteristics and occurrences of certain organ manifestations of
primary Sjögren’s syndrome (SS) in carbachol responder and non-responder SS patients
Responders (n=11) Non-responders (n=11)
Average age (y) 51.0 50.3
Average time since first symptom (y) 11.8 11.2
Articular involvement 9 8
Renal involvement 3 1
Bronchitis sicca 3 1
Pulmonary fibrosis 1 1
Raynaud’s phenomenon 5 1
Skin vasculitis 2 1
MALT lymphoma in parotid gland 2 0
For organ manifestations, numbers indicate the number of involved patients. For the precise defi-
nitions of articular and renal involvement, see table 1. No significant diVerence was found between
the two subgroups.
Table 4 Numbers of people with various degrees of
severity of skin dryness among the primary Sjögren’s
syndrome patients (n=22)
Degree of skin dryness 0 I II III IV
Number of patients 5 4 6 7 0
For a precise description of the assessment of the severity of skin
dryness, see the text (Methods section).
Microvascular response to cholinergic stimuli in SS 51
 o
n
 20 June 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/ard.59.1.48 on 1 January 2000. Downloaded from
 
muscarinic cholinergic agonist, carbachol. Ace-
tylcholine has been demonstrated to cause
vasodilatation in healthy humans.13 Although
the non-adrenergic–non-cholinergic transmit-
ter systems probably play a more important
part in the physiological vasoregulation in the
skin than do the cholinergic nerves, receptors
for acetylcholine can also be found in the cuta-
neous microvasculature.21 Carbachol has been
demonstrated to induce phospholipase C
dependent saliva secretion through stimulation
of the muscarinic cholinergic receptors in
human salivary acinar cells.22 23 The same mus-
carinic receptors have been implicated in the
cholinergic vasodilatation in human cutaneous
arterioles in response to body heat stress.13
These findings provide a basis for our choice of
an investigation of the cutaneous microcircula-
tion as a model of the parasympathetic
innervation of the salivary glands. Neverthe-
less, firm conclusions can be drawn only after
examinations directly involving the salivary
glands in SS patients.
We found that the average increase in
cutaneous microcirculatory blood flow in
response to carbachol was significantly smaller
in the SS patients than in the healthy controls.
In half of the SS patients, the reaction to a
potent parasympathomimetic drug was virtu-
ally absent or markedly diminished. As va-
sodilatation is characterised physiologically by
a decrease in vascular resistance, the CVR was
also calculated by dividing the mean arterial
pressure by SBF. As the arterial pressure
remained virtually unchanged in all the exam-
ined persons during the examinations, an
increase in SBF always reflected cutaneous
vasodilatation in this experimental setting.
The above finding lends support to previous
results suggesting a disturbance in the para-
sympathetic autonomic nervous system in SS.
As our experiments involved the administra-
tion of a muscarinic receptor agonist directly to
the examined target organ, the detected
unresponsiveness favours the hypothesis that a
dysfunction may exist at a receptorial or
post-receptorial level. To test whether a recep-
torial dysfunction may result from a structural
abnormality of the receptor protein caused by
an abnormal genetic coding, we determined
the HLA DRB1, DQA1 and DQB1 genotype
profiles in our study patients. Certain HLA
alleles (most importantly HLA-DR3) are
known to occur more frequently in SS patients
than in the general population. However, the
hypothesis that an acetylcholine receptor pa-
thology may be determined by a genetic
predisposition remains an open question, as
our relatively small patient population does not
allow firm conclusions in this regard. Anti-
receptor antibodies, similarly to myasthenia
gravis, may be other possible causes of a recep-
tor dysfunction. Indeed, antibodies against rat
M3 muscarinic receptors have been detected in
SS patients,9 though the existence and possible
role of anti-receptorial antibodies against
human muscarinic receptors have not been
verified.
It has been hypothesised that an interaction
may occur in the salivary glands between the
infiltrating inflammatory cells and certain
neuropeptides.4 In contrast, another hypothesis
suggests that the loss of trophic stimuli from
the parasympathetic nerves in the salivary
glands might be a cause of acinar cell atrophy,
and this may contribute to the decreased saliva
production.4 Our results relating to investiga-
tion of a target organ distant from the areas of
lymphocytic inflammation suggest that a disor-
der of the cholinergic receptors may not be
restricted to the exocrine glands, but may be a
more widely occurring phenomenon, and that
this defect is possibly independent of the local
inflammatory process. Further investigations
may yield results of general importance as con-
cerns the interactions between the nervous sys-
tem and the immune system.
As a considerable proportion of the SS
patients displayed a fundamentally insignifi-
cant reaction to carbachol, we could divide our
population of SS patients into responders and
non-responders to the cholinergic agent. The
occurrence of unresponsiveness did not corre-
late with the age of the patients, the disease
duration, the presence of a specific organ
manifestation (including vascular manifesta-
tions of the disease) or of an autoantibody, nor
the severity of the functional impairment of the
salivary and lachrymal glands. However, all the
organ involvements proved to be more com-
mon in the responder patients than in the non-
responders. Confirmation of this latter finding
with statistically significant results is first
necessary before an explanation can be sug-
gested.
In summary, we found that half of the exam-
ined SS patients proved to be non-responders
to the administration of the cholinergic recep-
tor agonist carbachol. Whether this unrespon-
siveness also relates to the clinically involved
exocrine glands, and the precise mechanism of
the disorder in the cholinergic innervation,
possibly at a receptorial or postreceptorial
level, are features that remain to be clarified.
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